NCT06549257View on ClinicalTrials.gov

Assessing the Safety, Immunogenicity and Ex-vivo Efficacy of Two Candidate Malaria Transmission Blocking Vaccines, Pfs25-IMX313 and Pfs45/48 Administered Alone and in Combination, in Matrix-M Adjuvant

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
Plasmodium Falciparum Malaria
Interventions
BIOLOGICAL

Pfs25-IMX313, Pfs48/45

Two soluble protein vaccines.

All Listed Sponsors
collaborator

European and Developing Countries Clinical Trials Partnership (EDCTP)

OTHER_GOV

lead

University of Oxford

OTHER